Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 53 min ago
Peer-reviewedCC BYFrontiers in immunology

Clinical features and outcomes of atezolizumab-associated encephalitis

  • Chunjiang Wang1
  • Wei Sun1
  • Liping Peng2
  • Shaoli Zhao3
  1. 1Department of Pharmacy, The Third Xiangya Hospital, Central South University , , ,
  2. 2Department of Cardiology, The Third Xiangya Hospital, Central South University , , ,
  3. 3Department of Endocrinology, The Third Xiangya Hospital, Central South University , , ,
Read full textPDFDOICite

Abstract

Background: To explore the clinical characteristics of atezolizumab-associated encephalitis and to provide clinical evidence for diagnosis and treatment.

Methods: Clinical reports on atezolizumab-associated encephalitis published before June 30, 2026 were collected for retrospective analysis by searching Chinese and English databases.

Results: A total of 39 cases of encephalitis were included, with a median age of 60 years (33, 78). The median time of symptom onset was 14 days (2, 420) after the initial administration. Fever (53.8%), confusion (51.3%) and headache (28.2%) were the main complaints of the patients. Cerebrospinal fluid examination showed elevated white blood cell count and protein, with median values of 27 cells/μL (1, 553) and 133mg/dL (27.1, 815), respectively. Brain magnetic resonance imaging showed T2 fluid-attenuated inversion recovery hyperintensities in half of the patients. Electroencephalogram showed display epileptiform discharges (26.7%) and slow waves (40.0%). After discontinuation of atezolizumab and initiation of targeted treatment, 97.4% of patients achieved symptomatic improvement or recovery, while 2.6% died of encephalitis-related complications.

Conclusion: Patients with atezolizumab-associated encephalitis were predominantly middle-aged and elderly, with fever, confusion and headache as the major manifestations. Clinicians should be alert to the potential risk of encephalitis during atezolizumab treatment. Most patients obtained symptom relief or clinical recovery following atezolizumab discontinuation and treatment; only a few succumbed to severe encephalitis-related complications.

Related

  1. Clinical features and long-term outcomes of anti-DPPX autoimmune encephalitis: a multicentre retrospective study in a Chinese cohort.
    Fuping Chen, Wendi Yu, Jing Peng +7
    BMJ neurology openPeer-reviewedCC BY-NCFull textNeurologyEurope PMCPMC
  2. Integrating Single-Molecule Variant Phenotyping with Clinical Features Predicts Outcomes in KIF1A-Associated Neurological Disorder
    A. Gennerich, W. Chung, L. Rao +7
    medRxivPreprintAll rights reservedFull textNeurologymedRxiv
  3. Early antibiotic exposure, but not late exposure, negatively affects the clinical outcomes of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
    Aryoung Kim, Myung Ji Goh, Byeong Geun Song +6
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  4. Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study.
    V Moreno, M Dorta, A Rueda +5
    Immuno-oncology technologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  5. Clinical characteristics and exploratory factors associated with in-hospital mortality in pediatric severe viral encephalitis
    Ping He, Fangqi Hu, Fei Wang
    Frontiers in pediatricsPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{wang2026clinical,
  title = {{Clinical features and outcomes of atezolizumab-associated encephalitis}},
  author = {Chunjiang Wang and Wei Sun and Liping Peng and Shaoli Zhao},
  journal = {Frontiers in immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1943615},
  url = {https://europepmc.org/article/PMC/PMC13668502},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Clinical features and outcomes of atezolizumab-associated encephalitis
AU  - Chunjiang Wang
AU  - Wei Sun
AU  - Liping Peng
AU  - Shaoli Zhao
PY  - 2026
DA  - 2026/10/01
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1943615
UR  - https://europepmc.org/article/PMC/PMC13668502
AB  - Background: To explore the clinical characteristics of atezolizumab-associated encephalitis and to provide clinical evidence for diagnosis and treatment.  Methods: Clinical reports on atezolizumab-associated encephalitis published before June 30, 2026 were collected for retrospective analysis by searching Chinese and English databases.  Results: A total of 39 cases of encephalitis were included, with a median age of 60 years (33, 78). The median time of symptom onset was 14 days (2, 420) after the initial administration. Fever (53.8%), confusion (51.3%) and headache (28.2%) were the main complaints of the patients. Cerebrospinal fluid examination showed elevated white blood cell count and protein, with median values of 27 cells/μL (1, 553) and 133mg/dL (27.1, 815), respectively. Brain magnetic resonance imaging showed T2 fluid-attenuated inversion recovery hyperintensities in half of the patients. Electroencephalogram showed display epileptiform discharges (26.7%) and slow waves (40.0%). After discontinuation of atezolizumab and initiation of targeted treatment, 97.4% of patients achieved symptomatic improvement or recovery, while 2.6% died of encephalitis-related complications.  Conclusion: Patients with atezolizumab-associated encephalitis were predominantly middle-aged and elderly, with fever, confusion and headache as the major manifestations. Clinicians should be alert to the potential risk of encephalitis during atezolizumab treatment. Most patients obtained symptom relief or clinical recovery following atezolizumab discontinuation and treatment; only a few succumbed to severe encephalitis-related complications.
SN  - 1664-3224
ER  -